Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …

This position statement from the Heart Failure Association of the European Society of
Cardiology Cardio‐Oncology Study Group in collaboration with the International Cardio …

Aims This observational study characterized cardiovascular disease (CVD) mortality risk for
multiple cancer sites, with respect to the following:(i) continuous calendar year,(ii) age at …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies
that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual …

Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been
linked with potentially limiting cardiotoxicity, including emerging reports of profound …

Abstract Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose
considerable challenges for the management of oncology patients. COVID-19 presents as a …

Mitochondria has an essential role in myocardial tissue homeostasis; thus deterioration in
mitochondrial function eventually leads to cardiomyocyte and endothelial cell death and …